Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | anti-thymocyte globulin + BKT140 + Cyclosporine + Methylprednisolone |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BKT140 | TN14003|BL-8040|BL8040|Motixafortide | CXCR4 Inhibitor 15 | BL-8040 (BKT140) is a selective CXCR4 antagonist that prevents SDF-1 (CXCL12) binding, which may lead to decreased tumor growth (PMID: 21138752). | |
| Cyclosporine | Sandimmune | Ciclosporin | ||
| Methylprednisolone | Artisone-Wyeth | 6alpha-Methylprednisolone | ||
| anti-thymocyte globulin | Thymoglobulin | lymphocyte immune globulin|ATGAM | Thymoglobulin (anti-thymocyte globulin) is an immunoglobulin that binds to and destroys T-lymphocytes, which may aid in reduction of graft-vs-host disease when administered with stem cell transplantation (PMID: 32624582). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02462252 | Phase II | anti-thymocyte globulin + BKT140 + Cyclosporine + Methylprednisolone | Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome | Completed | USA | 0 |